dr. eric sherman on the sequencing of cabozantinib and vandetanib for mtc
Published 11 years ago • 697 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:54
dr. eric sherman discusses vandetanib's dosage and precautions
-
2:41
dr. sherman comments on cabozantinib and vandetanib in medullary thyroid cancer
-
1:29
dr. sherman discusses the vandetanib trial
-
2:20
dr. sherman on pazopanib in anaplastic thyroid cancer
-
4:42
treatment-related toxicity in advanced medullary thyroid cancer
-
55:43
cabozantinib for radioiodine-refractory differentiated thyroid cancer with dr. sherman
-
1:16
dr. ezra cohen discusses the cabozantinib dose size and tolerability
-
0:47
dr. sherman discusses the development of selumetinib
-
1:30
dr. sherman on selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
-
1:11
dr. langmuir on the advantages of vandetanib in medullary thyroid cancer
-
0:59
dr. ezra cohen discusses the cabozantinib exam trial
-
5:59
multidisciplinary treatment of medullary thyroid cancer
-
0:43
cabozantinib's targeting potential
-
6:30
cabozantinib: the meteor trial
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
1:27
dr. ezra cohen on the efficacy and pharmacokinetics of cabozantinib
-
1:47
dr. sherman on the relationship between thyroid-stimulating hormone levels and outcomes from select
-
8:05
genetic testing and screening in medullary thyroid cancer
-
1:10
dr. langmuir explains the side effects of vandetanib